Navigation Links
OHSU turns innovations into commercial opportunities at record pace
Date:10/23/2007

s to establish. The National Institutes of Health, which allocates more than $4 billion annually toward infectious disease research, funds strong infectious disease research programs at Oregons research universities. The company will work closely with the universities to turn discoveries into products that improve peoples health. [ For more information about ID Biopharma, go to http://www.idbiopharma.com ]

  • Yecuris, Inc. plans to launch products that will use novel technologies to address the problem of liver toxicity, one of the primary obstacles to safe and efficient drug development. When new drug compounds are being developed they need to be tested on human liver cells to predict how the human liver will metabolize it. One in six compounds fail in the development stage because of liver toxicity. The market demand for such cells has reached an estimated $2 billion a year worldwide, but the supply is spotty. The company founded by Markus Grompe, M.D., professor of molecular and medical genetics, and pediatrics, OHSU School of Medicine, and director of the Oregon Stem Cell Center anticipates providing an economical and reliable source of these cells based on a technology that, in essence, turns a mouse into a factory for human liver cells. [ See OHSU press release: http://www.ohsu.edu/ohsuedu/newspub/releases/livercells080907.cfm ]

  • Cylerus a company founded by Stephen Hanson, Ph.D., head of the OHSU Department of Biomedical Engineering is developing technological improvements that will enable uniform, localized drug delivery for preserving the functions of artificial blood vessels (vascular grafts). These advances will address the unmet medical need to prevent vascular graft failure that currently results from localized blood clotting and abnormal tissue ingrowth within such grafts. The co
    '/>"/>

Contact: Harry Lenhart
lenharth@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Lack of enzyme turns fat cells into fat burners
2. Programmable cells: Engineer turns bacteria into living computers
3. Gene therapy turns off mutation linked to Parkinsons disease
4. Hopkins researchers discover genetic switch that turns off an oxygen-poor cells combustion engine
5. Jefferson researchers uncover new way nature turns genes on and off
6. Leukemia drug turns mini-molecules up, cancer genes down
7. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
8. Why were the HIV prevention trials in commercial sex workers abandoned?
9. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
10. Hopkins study suggests commercially available antibiotic may help fight dementia in HIV patients
11. Commercial fishing causes dangerous fluctuations in fish populations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... in French . , Prof. Claudio Cuello at ... can emulate Alzheimer,s disease in humans, enabling research that will ... brain condition leading to a progressive decline of memory and ... in the past, rats are more intelligent than other rodents ...
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-03/sfeb-ftc032910.php,">Chinese ... known antiepileptic agent widely used throughout the world. ... have suggested that, as for other anticonvulsant drugs ... including valproate and carbamazepine, phenytoin may have mood-stabilizing ...
... Helmholtz Zentrum Mnchen has launched a new cooperative project ... therapeutic approaches against lymphoid tumors. With a two-year grant ... two partners will seek to further develop lentiviral vector ... cancer form and to devise approaches for treatment. ...
Cached Biology News:From the clinics to the bench and back -- phenytoin as a mood stabilizer? 2Development of new anti-cancer gene therapy approach using lentiviral vectors 2
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
(Date:7/29/2015)... +14% CER / 20% of sales) led the regional performance in the second ... well as solid contributions from Korea, India and ... East / Africa (Q2 2015: +3% CER ... Turkey and the United Kingdom . The ... HPV sales, on demand across all customer classes. The top seven emerging markets ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... ... that have $1 - $20 million in yearly revenues and have experienced significant growth over ... , ... September 24, 2009 -- Orange County has become a hub for innovation and growth and ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a new market ... World Market for Cancer Therapeutics and Biotherapeutics, 3rd. ... http://www.reportlinker.com/p0119229/World-Market-for-Cancer-Therapeutics-and-Biotherapeutics-3rd-Edition-The.html , , ... year. This number is expected to increase by 2.4% by 2020 ...
... , , WAYNE, ... Bonatti, M.D., Professor of Surgery and Director of Coronary Surgery ... Center in Baltimore, has completed the world,s first use of ... robotic and fully endoscopic heart surgery. The new cardiopulmonary bypass ...
Cached Biology Technology:Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report 11MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 2MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 3MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System 4
Without sodium bicarbonate. Sterile, Cell culture tested...
... a fluorescence scanner with 1 or 2 ... Protein, CGH, ) spotted on standard slides ... InnoScan700 scanners include three different models:, ... simultaneous dual fluorescence scanner (635nm and 532nm). ...
... Open Frame DNAscope is an integrated confocal ... and readily integrated into your specific application. ... we can tailor the system to your ... optical scanning design has been modularized and ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
Biology Products: